[Comparative prospective study of effects of Biovisc and Healonid on endothelial cell loss and intraocular pressure in cataract surgery].
OBJECTIVE
The goal of this trial was to evaluate the efficacy (protective action on corneal endothelium and ability to facilitate the procedure) as well as safety (effect on intraocular pressure and inflammation) of Biovisc (new viscoelastic agent made of 1% sodium hyaluronate produced by bacterial fermentation) versus Healonid) postcataract surgery (manual or phacoemulsification).


METHODS
106 patients, 45 males and 61 females (31-94 years) were included in this prospective randomized multicentre trial and followed up for three months. Specular microscopy and intraocular pressure (IOP) measurement were the main evaluation criteria.


RESULTS
At D 90, no significant difference was observed between the two viscoelastic agents on the mean endothelial cell loss (group Viovis: -8.6%; group Healonid: -6%) as well as on IOP (early peaks were transitory and resolutive).


CONCLUSIONS
Biovisc and Healonid were similar in terms of efficacy and tolerance.
Colin
J
J
Hôpital Morvan, Brest.
Renard
G
G
Ullern
M
M
Lablache Combier
M
M
Richard
C
C
Trinquand
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002387:Cataract Extraction / Q000379:methods; D002452:Cell Count; D004728:Endothelium, Corneal / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology*; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000379:methods*; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies
D006820:Hyaluronic Acid
Etude prospective comparative des effets du Biovisc et du Healonid sur la perte endothéliale cellulaire et de la pression intraoculaire dans la chirurgie de la cataracte.